NEW YORK (GenomeWeb News) – Rosetta Genomics today said that the New York State Department of Health has given conditional approval for the company's Rosetta Kidney Cancer Test for patient samples originating from New York.

As a result of the conditional approval, the test is now available in all 50 states in the US. However, Rosetta will have to provide any additional information within 60 business days to NYDOH as requested as part of the conditional approval, the Israel-based developer of microRNA-based molecular diagnostics tests said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.